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Abstract 
Objective: We analyzed clinical and psychosocial factors in patients with refractory 
psychogenic nonepileptic seizures, seeking characteristics that could hasten diagnosis. 
Background: Psychogenic nonepileptic seizures remain a diagnostic challenge. 
Prognosis is best if patients are treated within 2 years of symptom onset. Psychosocial 
factors have been shown to provide important information for differential diagnosis. 
Methods: Over a year and 1132 consecutive patients, our hospital’s Epilepsy Unit 
suspected 93 patients of having psychogenic nonepileptic seizures and confirmed 
refractory psychogenic nonepileptic seizures in 67. We referred these patients to our 
psychiatric consultation unit for detailed diagnostic interviews, and 53 of them followed 
through. Two months after the psychiatric evaluation we gave them a psychiatric 
intervention, explaining the diagnosis and treating their comorbidities. We also tracked 
the patients’ use of antiepileptic drugs for 3 months, from just before the psychiatric 
evaluation until a month after they started the intervention. 
Results: Women, patients with an inadequate primary support group, and patients who 
had tried many antiepileptic drugs were most likely to have their diagnosis of 
psychogenic nonepileptic seizures delayed by >2 years after onset. A stepwise logistic 
regression showed that the 2 best predictors of late diagnosis were lack of availability of 
a primary support group and patients trying many antiepileptic drugs. 
Conclusions: Clinicians evaluating patients with questionable seizures should raise 
their suspicion of psychogenic nonepileptic seizures especially in female patients with 
an insufficient primary support group and a history of taking multiple antiepileptic 
drugs.  
Key Words: psychogenic nonepileptic seizure, epilepsy, early diagnosis, antiepileptic 
drug, psychosocial factors 
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Psychogenic nonepileptic seizures (PNES) are transient paroxysmal events that affect 
aspects of behavior, perception, sensation, or consciousness in ways that mimic 
epileptic seizures. The overlap in symptoms makes continuous video-
electroencephalography (EEG) recording the gold standard test to distinguish PNES 
from true epileptic seizures. However, video-EEG is not always available. This poses a 
major challenge to diagnosing PNES (O’Sullivan et al, 2006; Parra et al, 1999). 
PNES is a psychiatric diagnosis that is usually made after ruling out organic 
diseases. Although there has been some research into patterns of emotional 
dysregulation among patients with PNES (Uliaszek et al, 2012), the lack of a defined 
psychiatric characterization of the disorder contributes to an estimated diagnostic delay 
of about 8 years (Bodde et al, 2009a). Early diagnosis of PNES helps patients avoid 
unnecessary antiepileptic drug treatment and is a major determinant of better long-term 
prognosis (Buchanan and Snars, 1993; Lempert and Schmidt, 1990). 
According to a critical review by Bodde et al (2009b), the psychiatrist evaluating 
patients with refractory PNES needs to recognize the disorder’s psychosocial as well as 
clinical aspects. It is important to identify psychiatric disorders and psychological 
stressors that might be treated (Tojek et al, 2000). In particular, the psychiatrist should 
determine whether patients have an unstructured family, social, or job environment, 
because this can play a role in the pathogenesis of PNES and is a potential target for 
psychotherapeutic intervention (Bodde et al, 2012). 
This study examined the role of clinical and psychosocial aspects of PNES in 
delaying the diagnosis for patients who were eventually found to have refractory PNES. 
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METHODS 
This was a cross-sectional study of patients with refractory PNES, with 
additional follow-up of the patients’ antiepileptic drug use. The patients had been 
referred to us at the Consultation Liaison Psychiatry Unit of the Hospital Universitari 
Vall d’Hebron, a tertiary referral center in Barcelona, Spain.  
Of 1132 consecutive patients seen at the Epilepsy Unit over the course of the 
year 2012, PNES was suspected in 93 (Figure 1). Three of our experienced 
epileptologists (authors M.T., X.S.P, and E.S.) gave the patients a full diagnostic work-
up that included clinical evaluation, neuroimaging, conventional EEG, video-EEG, and 
long-term follow-up visits. The 3 epileptologists concurred in diagnosing refractory 
PNES in 67 (73%) of the 93 patients. For the purposes of the study, we defined 
refractory PNES as PNES that had a major impact in a patient’s quality of life. We 
studied only those patients whose PNES was refractory.  
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FIGURE 1. Sequence of patient evaluations for psychogenic nonepileptic seizures 








1132 patients visited the Epilepsy Unit 
Referral to the Consultation Liaison Psychiatric Unit 
 
93 patients had suspected PNES 
 
26 patients did not get 
a confirmed diagnosis 
 
67 patients had refractory PNES confirmed 
• 39 had their diagnosis delayed by >2 years 
• 19 had PNES + true epilepsy 
• 61 had their antiepileptic drug use tracked for 3 months 
 
14 patients did not accept the referral but were 
statistically similar enough to the other 53 to be 
included in some analyses; antiepileptic drug 
use is reported for 8 of these patients 
53 patients were evaluated 
• 39 had a psychiatric disorder 
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The epileptologists determined that of the 26 remaining patients, some had 
nonrefractory PNES and others had conditions that made it impossible to diagnose 
PNES, eg, severe mental retardation, acute or severe medical conditions, or inability to 
complete the medical interview. 
As recommended by the guidelines of the International League Against Epilepsy 
(Kerr et al, 2011), the 3 epileptologists explained the PNES diagnosis to each of the 67 
patients in a clear, positive, nonpejorative manner, and then discussed the need for the 
patients to cut back on or stop the antiepileptic drugs that they had been taking. The 
epileptologists offered each patient an evaluation at our Consultation Liaison Psychiatry 
Unit; 53 (79%) of the patients followed through. 
One consultant psychiatrist (author A.R.U) evaluated each of the 53 patients. 
Before starting the evaluation, she recorded the number of antiepileptic drugs that the 
patient was taking; she did not record drug doses. Then she gave the patient a standard 
diagnostic evaluation comprising a semi-structured interview established by hospital 
consultation-liaison protocol, and the Structured Clinical Interview (First et al, 2002) for 
the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Axis I 
disorders, text revision (American Psychiatric Association, 2000). Depending on the 
patient’s psychiatric history, these interviews took 1 to 3 sessions, all held during the 
same week and lasting for a total of 2 to 6 hours.  
With these clinical interviews, the psychiatrist obtained background about 
psychosocial factors such as the patients’ work, financial and social status, and 
availability of and problems with their primary support group, as defined by the 
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision Axis 
IV criteria (American Psychiatric Association, 2000). Using the psychiatrist’s notes, we 
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recorded separately the “availability of” and “problems with” each patient’s primary 
support group. 
After completing the psychiatric evaluations, the psychiatrist agreed with the 3 
epileptologists that all 53 patients had refractory PNES. 
We then gave each patient a personalized psychiatric intervention. For most of 
the patients, we started the intervention 2 months after the psychiatric evaluation. First, 
we explained to patients the cause of their symptoms. Then we treated any psychiatric 
comorbidities, with medication if necessary. We continued reducing the patients’ 
antiepileptic drugs, following the epileptologists’ recommendations noted in the 
medical record. As needed, we changed the patients to different antiepileptic drugs that 
were more suitable given their psychiatric disorder. Also as needed, we referred patients 
to our consultation liaison clinical psychologist (author S.G.F.). We continued the 
intervention for as long as each patient needed it. Some patients remained in long-term 
psychiatric treatment. 
As mentioned, before beginning the psychiatric evaluation the psychiatrist had 
recorded the number of antiepileptic drugs that the patients were taking. As a follow-up, 
1 month into the psychiatric intervention she again recorded the number of antiepileptic 
drugs that the patients were taking. Thus, we had drug records covering a 3-month span, 
starting 2 months before the intervention and continuing 1 month into it. We will here 
call these 3 months the drug “tracking period.” 
As noted, 14 (21%) of our original 67 patients with confirmed refractory PNES 
did not accept our offer to be evaluated at the Consultation Liaison Psychiatric Unit. 
However, 8 of these patients continued to attend their scheduled outpatient visits at the 
Epilepsy Unit.  There they received an explanation of the cause of their symptoms and 
their antiepileptic drug use was tracked. We found no statistical differences between 
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these 14 patients and the other 53 patients in age, sex, or types of psychogenic seizures. 
We included the 8 patients in our demographic analyses reported in Table 1, our 
antiepileptic drug use calculations, and our predictive model of diagnostic delay. 
The study project was approved by the local Research Ethics Committee (PR 
AG 232-2011). All participants gave written informed consent before taking part. 
 
Statistical Analyses 
We divided our 67 patients into 2 groups: those who had had their PNES 
symptoms for ≤ 2 years before we confirmed their diagnosis, and those who had had 
their symptoms for > 2 years. We chose a 2-year cut-off point because the existing 
literature had established that intervention within 2 years is most likely to improve 
prognosis (Bodde et al, 2012; Buchanan and Snars, 1993).  
As an independent variable, we chose a mixed diagnosis of PNES plus true 
epilepsy. Patients who have both disorders should be considered as clinically different 
from those who have PNES alone, especially regarding antiepileptic drug treatment.  
We used odds ratios (for dichotomous categorical variables), chi-squared tests 
(for categorical variables with ≥ 3 levels), and t tests (for continuous variables) for 
comparisons between groups and repeated measures of the number of drugs prescribed. 
We used nonparametric techniques (Mann-Whitney, Kruskal-Wallis, and Wilcoxon 
tests) for comparisons when the sample size was insufficient or variables were not 
normally distributed. Finally, we performed a stepwise logistic regression using 
variables that we had found to be statistically different (P < 0.05) between the patient 
groups with earlier and later diagnosis. 
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For all analyses, we used SPSS 18.0 for Windows (SPSS Inc, Chicago, Illinois). 




For our 67 patients with confirmed refractory PNES, the mean delay from onset 
of symptoms to confirmation of the diagnosis was 7 ± 8 years (range: 0 to 33 years). 
Only 28 (42%) of the patients received an early diagnosis, within 2 years of PNES 
onset. The other 39 (58%) were diagnosed after 2 years. For our subgroup of 53 patients 
who had agreed to psychiatric evaluation, the percentages were the same: 22 received a 
diagnosis within 2 years and 31 received a diagnosis after 2 years. 
 
Sociodemographics 
Table 1 lists the sociodemographic findings for our 67 patients. More women 
than men were diagnosed ≥ 2 years after onset (odds ratio = 0.346, 95% confidence 
interval = 0.121-0.991, P > 0.05). Patients with a primary support group were more 
likely to be diagnosed within 2 years (odds ratio = 8.280, 95% confidence interval = 
0.972-70.529, Fisher’s P > 0.05). More than 60% of the patients had disrupted family 
dynamics and environmental psychosocial stressors, but these factors did not contribute 
significantly to diagnostic delay. 
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social data are incomplete for some of the 14 patients who did not accept psychiatric referral. For these 14 patients: 
Education n = 3. Work status n = 4. Marital status n = 10. Children n = 14. Availability of a primary support group n 
= 10. Problems with primary support group n = 12. Other psychosocial or environmental problems n = 2. 
 
M = mean. SD = standard deviation. 
 
Types of PNES Events 
In our 67 patients, we did not find significant differences between the types of 
psychogenic seizures experienced by the groups with early and late PNES diagnoses 
(Table 2). Most common in both groups were major motor seizures (affecting 62% of 
 
Time of PNES Diagnosis 
Significance 
Early (≤2 years)  
(n = 28) 
Late (>2 years)  
(n = 39) 
 M SD M SD t P 
Age 37.75 16.48 39.95 11.43 -0.609 0.546 
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the 67 patients), followed by minor motor (37%) and nonmotor (30%) seizures; 31% of 
the patients had 2 or more types. 
TABLE 2. Seizure Types and Psychiatric Diagnoses in Patients with Refractory 
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Of our 67 patients, 19 (28%) had a mixed diagnosis of PNES and true epilepsy 
(Table 2). We found no significant differences in the prevalence of combined PNES and 
epilepsy between the groups with early and late PNES diagnoses. Neither did we find a 
significant difference between the pure PNES group and the mixed diagnosis group in 
any sociodemographic variable or in the types of seizures experienced. 
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Psychiatric History 
Of the 53 patients who underwent psychiatric evaluations, 39 (74%) had a 
history of a psychiatric disorder (Table 2). We did not find significant differences 
between the early and late diagnosis groups for psychiatric conditions. The most 
frequent diagnoses were depression in 17 (32.1%) of the 53 evaluated patients, anxiety 
in 15 (28.3%), other conversion disorders in 14 (26.4%), adjustment disorder in 11 
(20.8%), and personality disorder in 8 (15.1%). A definitive psychiatric diagnosis was 
difficult to obtain in some of the patients because of their long histories of diffuse 
symptoms and of seeking care from multiple specialists. 
Three patients, 2 of whom had pure PNES and 1 who had a mixed diagnosis, 
were at high risk for suicidal thoughts. All 3 patients had been taking several 
antiepileptic drugs. However, we could not prove an association between the patients’ 
suicidal thoughts and any specific antiepileptic drug and/or the reduction in the number 
of drugs that the patients took during the tracking period. 
 
Antiepileptic Drug Treatment 
For our 53 patients, we compared antiepileptic drug use between the groups with 
early and late PNES diagnosis. Not surprisingly, the patients with an early diagnosis had 
tried fewer antiepileptic drugs (mean of 1.59 ± 1.30) than those with a late diagnosis 
(mean of 2.55 ± 1.82); t = -2.111, P < 0.05. 
We calculated the reduction in number of antiepileptic drugs that the patients 
took during the 3-month tracking period, from just before the psychiatric evaluation to 1 
month into the intervention. The reduction was greater in the late diagnosis group 
(average reduction: -1.32 ± 1.60) than the early diagnosis group (-0.68 ± 0.99), but did 
not reach statistical significance (t = -1.794, P = 0.079). At the end of the month, the 
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groups had a nonsignificant difference in the mean number of antiepileptic drugs that 
they were taking: 0.91 ± 0.87 in the early diagnosis group versus 1.23 ± 1.38 in the late 
diagnosis group; t = -1.022, P = 0.312. 
Of the 14 patients who had refused referral for psychiatric evaluation, we were 
able to track drug use in 8 because they continued to visit the Epilepsy Unit. When we 
added these 8 patients’ drug numbers to our calculations and analyzed the resulting 
group of 61 patients, we found significant differences for drugs taken at the start of the 
tracking period (1.46 ± 1.27 for the early diagnosis group versus 2.72 ± 1.93 for the late 
diagnosis group; t = -2.896, P < 0.005) and for reduction of use during the 3 months 
(0.62 ± 0.98 for the early diagnosis group versus 1.46 ± 1.79 for the late diagnosis 
group; t = -2.167, P < 0.05). We found a nonsignificant difference for drugs taken at the 
end of the 3 months (0.88 ± 0.86 for the early diagnosis group versus 1.26 ± 1.34 for the 
late diagnosis group; t = -1.241, P = 0.220). 
Among the 53 patients who had accepted psychiatric evaluation, those with a 
mixed diagnosis started the tracking period taking 3 ± 1.80 antiepileptic drugs versus 
1.85 ± 1.59 in the group with PNES alone; t = 2.293, P < 0.05. Over the 3 months, both 
groups had essentially identical mean reductions: -1.07 ± 1.33 drugs in the patients with 
a mixed diagnosis versus -1.05 ± 1.45 in the patients with PNES alone; t = 0.046, P = 
0.964. However, a month into the intervention, the groups were taking a significantly 
different number of drugs: a mean of 1.93 ± 1.21 in the mixed diagnosis group versus 
0.79 ± 1.06 in the group with PNES alone; t = 3.319, P < 0.005. The results were 
virtually identical when we added the 8 patients whose drug use was tracked despite 
their refusing psychiatric evaluation. 
In the 53 patients who had accepted psychiatric evaluation, we compared the 
most-used antiepileptic drugs in the 14 patients who had a mixed diagnosis against the 
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most-used drugs in the 39 patients who had pure PNES.  At the start of the tracking 
period, of the 14 patients with mixed diagnoses, 8 (57.1%) were taking levetiracetam, 7 
(50%) valproate, and 4 (28.6%) carbamazepine. At the end of the 3 months of tracking, 
6 patients (42.9%) were taking levetiracetam, 4 (28.6%) valproate, and 4 (28.6%) 
clonazepam. In contrast, at the start of tracking, of the 39 patients with pure PNES, 17 
(43.6%) were taking levetiracetam, 13 (33.3%) valproate, and 7 (17.9%) clonazepam. 
Three months later, 6 of the patients (15.4%) were taking levetiracetam, 6 (15.4%) 
clonazepam, and 4 (10.3%) valproate. 
 
Predictors of Diagnostic Delay 
Among the 61 patients whose antiepileptic drug use we could track, the 
variables that differed statistically between the groups with early and late diagnosis 
were female sex, primary support group availability, and past antiepileptic drugs. We 
used these variables to construct a stepwise logistic regression model. The regression 
results showed that the main predictors of diagnostic delay were lack of an available 
primary support group (odds ratio = 12.445, 95% confidence interval = 1.304-118.731) 
and a higher number of past antiepileptic drugs taken (odds ratio = 1.889, 95% 
confidence interval = 1.203-2.999). Despite these broad confidence intervals, the model 
had an acceptable goodness of fit, with 88.6% sensitivity and 52% specificity, 73.3% 




It is relatively common for patients to present to clinicians with complaints that 
turn out to be PNES. The patients in our study had seizures for an average of 7 years 
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before they received an accurate diagnosis. Many of our patients had disrupted family 
dynamics, despite a primary support group. The typical patient who was diagnosed > 2 
years after the onset of symptoms was a woman who lacked a primary support group 
and who had tried several antiepileptic drugs. 
Our results point out that psychosocial factors should be considered in 
confirming a PNES diagnosis. Our sample’s main demographic and social 
characteristics were in line with the literature: middle age, mostly women, most patients 
with only a primary education, and most with chronic social stressors (Abubakr et al, 
2003; Baillès et al, 2004; Bodde et al, 2009b; Galimberti et al, 2003; Reuber, 2008; 
Reuber and Elger, 2003). Family dysfunction during a patient’s childhood has been 
reported as a causal factor in PNES, and many studies have shown it to be both a 
possible etiology and a therapeutic target (Krawetz et al, 2001; Moore et al, 1994; 
Salmon et al, 2003). As noted, many of the patients in our sample had disrupted family 
dynamics and environmental and psychosocial stressors, despite a primary support 
group. In 2011, LaFrance et al reported that family dynamics could help predict these 
patients’ quality of life. 
The prevalence of PNES in epilepsy units has been estimated at 15% to 30% of 
patients (Bodde et al, 2009a). Most published series describe similar rates among 
patients with drug-resistant epilepsy. However, the rate of confirmed PNES in our study 
was only 6% (67 of 1132 consecutive patients).  
This low prevalence has several possible explanations. One is that our patients 
came from an epilepsy unit that treats patients with a wide variety of seizure disorders, 
not just antiepileptic drug-refractory disease. Furthermore, we included in our study 
only patients whose PNES was making a major impact on their quality of life. Our 
ability to confirm PNES was also limited by the difficulty of the diagnosis: We were 
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never able to confirm suspected PNES in 26 (28%) of the 93 patients in whom we 
suspected it, even with highly experienced diagnosticians, long-term follow-up, and 
availability of prolonged video-EEG monitoring (Bodde et al, 2009a, 2009b). 
Despite physicians’ best efforts to explain PNES in a non-threatening way, some 
patients reject the diagnosis. This issue has prompted psychiatrists and epileptologists to 
create guidelines for the best ways to communicate the diagnosis (Hall-Patch et al, 
2010). In our study, we used these guidelines to explain the diagnosis to our 67 patients 
with confirmed PNES. Even then, when we referred them to the Consultation Liaison 
Psychiatry Unit, 14 (21%) did not keep their appointment, although 8 of them continued 
to visit the Epilepsy Unit. The potential stigma of a psychiatric diagnosis and the belief 
that their recovery depended more on somatic than psychological factors may have 
scared the patients away (Stone et al, 2004). 
A high proportion of patients with PNES have comorbid psychiatric disorders 
(Reuber, 2008). In our sample, 74% of the patients who underwent psychiatric 
evaluation were found to have psychiatric disorders, mainly depression and anxiety. 
However, many of our patients had a long history of poorly defined psychological or 
psychiatric issues and treatments by other physicians, thus hindering standard 
psychiatric diagnosis (Bodde et al, 2012). Correctly identifying psychiatric 
comorbidities could play an important role in treating patients with PNES. As 
mentioned above, so could detection of disrupted psychosocial factors (Kanner et al, 
2012). 
Early diagnosis is essential to improve the prognosis of patients with PNES 
(Bodde et al, 2009b, 2012; Buchanan and Snars, 1993). In our study, the patients who 
received a late diagnosis were mostly women, lacked primary support, and had a history 
of inappropriate antiepileptic drug use. We cannot say with certainty why more women 
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received a late diagnosis. All these findings may indicate that diagnosing and treating 
patients with PNES requires a biopsychosocial model of illness, focusing on family 
dynamics (McHugh and Slavney, 1998). 
The main reason that patients with PNES are given unnecessary antiepileptic 
drugs is that they are believed to have drug-resistant epilepsy (Müller et al, 2002). 
Among our patients with and without true epilepsy, the highest percentage took the 
potentially hazardous drug levetiracetam (Hurtado et al, 2006). Patients can be spared 
the side effects of antiepileptic drugs through the combined efforts of the epileptologist 
and psychiatrist (Müller et al, 2002). In our study, a month after they began the 
psychiatric intervention, patients were taking significantly fewer antiepileptic drugs than 
3 months earlier. Still, most of the patients had to continue antiepileptic drugs for a time 
after the start of the intervention because tapering in patients with PNES usually 
requires slow titration. 
We tried to stop—or at least reduce the number of—antiepileptic drugs that our 
patients were taking, to minimize the potential for further psychological and systemic 
effects. For patients with combined PNES and epilepsy, we tried to continue just 1 drug, 
to prevent the epileptic seizures. For patients with pure PNES, we tried to stop all drugs. 
When making these attempts, we explained to the patients that antiepileptic drugs 
cannot help treat PNES and can actually be dangerous.  
However, many of our patients, especially those with longstanding disease, 
could not tolerate stopping their drugs. When the doses were lowered or tapered off, 
patients started complaining of feeling uncomfortable or having neuropsychiatric 
symptoms like irritability and emotional lability. Many patients started taking the drugs 
again on their own. If taking medication made patients feel better, we did not insist that 
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they abandon their drugs immediately, even such a risky drug as levetirazetam. Instead, 
we monitored their continuing drug use and encouraged them to stop eventually.  
Our study had several limitations. Conducted in a tertiary care setting, the study 
included only a small number of patients with confirmed PNES that had a major impact 
on their quality of life. Further, there was no control group. Finally, because of a lack of 
time and resources, we could not give a structured interview for personality disorders. 
Although the lack of information on personality disorders limits the reliability of our 
findings on comorbid psychiatric disorders in the sample, this lack also reflects real 
daily practice, where we hope our results can be applied. Overall, however, these 
limitations may hamper the generalizability of our results to other clinical settings. 
In conclusion, it can take many years for patients with PNES to receive an 
accurate diagnosis. Most patients with a long diagnostic delay are women, suffer from a 
lack of a primary support group, and have tried several antiepileptic drugs. Most 
predictive of late diagnosis are a lack of a primary support group and more antiepileptic 
drugs. However, with adequate intervention, some patients can reduce their use of 
antiepileptic drugs. Addressing disrupted family dynamics in these patients may be an 
important factor in treatment. 
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